Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Jazz Pharmaceuticals plc | a2016jpm8-k.htm |
Exhibit 99.1
Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 11, 2016:
Bruce C. Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc
…
2015 was a very significant year for our company. Good top- and bottom-line growth.
…
I will point out I will make forward-looking statements today. Actual results may differ materially and, obviously, forward-looking statements are subject to risks and uncertainties that we detail in our SEC filings.
…
Finally, I will refer to guidance in this presentation. That guidance is as we presented it on November 9 and it is as of that date, unless I specifically update it today.
…
With reference to slide 3: For 2015, we do expect to meet our prior guidance on the top line. That would represent about 13% or 14% top-line growth over 2014 with most of that growth and most of those revenues coming, as you can see in the pie chart on the right, from our core products.
…
With reference to slide 4: 2015 was a record year for us, both in terms of patients on drug and bottles shipped, but the year was significantly impacted by the implementation of our REMS starting in the third quarter. Pharmacy operations have stabilized and we believe the REMS implementation is behind us. We did end the year with 6% volume growth and we do expect to meet our financial revenue guidance for the year.
…
With reference to slide 5: We expect our Erwinaze revenues will also meet our prior guidance of $200 million to $210 million in sales for 2015.
…
With reference to slide 6: We do expect to meet our guidance on revenues for Defitelio for 2015.
…
Relevant slides from Jazz Pharmaceuticals plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 11, 2016:
